An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.

@article{Olmos2011AnEO,
  title={An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.},
  author={David Olmos and Jeremy Clark and Daniel R. Brewer and Lorraine Barwell and Gerhardt Attard and Alison H. M. Reid and Shahneen K. Sandhu and Andrea Zivi and Diletta Bianchini and N Babu Oomen and Emilda Thompson and L. Rhoda Molife and Stanley B. Kaye and Christopher C. Parker and Colin S. Cooper and Robert J.D. Jones and J. S. de Bono},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4577}
}
4577 Background: Prostate cancer (PCa) is the commonest male cancer in the Western world. Its biology and prognosis are heterogeneous and improved tools are needed to predict outcome more reliably. Here we studied the feasibility and clinical utility of whole blood mRNA expression array studies for this purpose. METHODS Whole blood samples were collected into PaxGene tubes between 08/2007 and 04/2008 from 100 PCa patients (pts): 31 good prognosis pts selected for active surveillance (AS) and… CONTINUE READING